Co-op: Enhanced Delivery of Biotherapuetics to CNS
Posted on: 15 Mar 2021
Cambridge, MA
Job Description
Job Description
This is for a 6-month position from July - December 2021.
We are seeking a Co-op to join Biogens Biologics Drug Discovery Team, and contribute to our mission to design, optimize, and develop therapeutics to improve the lives of patients with neurodegenerative diseases. In this role, you will contribute to a cross-functional effort to identify and validate novel technologies and modalities for enhancing systemic delivery of therapeutic candidates to the central nervous system (CNS).
Position Description:
Performing in vitro quantitative assays to support assessment of CNS delivery/ targeting properties of biotherapeutics: Meso-Scale Discovery-Electrochemiluminescence (MSD-ECL) or ELISA based assay to measure concentration of therapeutic antibodies in tissue culture media from in vitro functional assays as well as in rodent serum and tissue extracts from in vivo studies. Other activities will include maintaining cell culture lines and cell-based transwell model systems, as well as assessment of cell-surface receptor binding for BBB targeted antibodies using flow cytometry. Quantitative data analysis using Excel, Prism or other relevant software systems and reporting will be expected. Previous cell culture experience is preferred. There will also be an opportunity to receive in vivo training and participation in rodent CNS biodistribution studies.
Qualifications
To participate in the Biogen Intern or Co-op Program, students must meet the following eligibility criteria:
* Legal authorization to work in the U.S.
* Enrollment in a full-time undergraduate or graduate program, returning to the academic program following Biogen Intern or Co-op assignment
* Minimum grade point average of 3.2 preferred
* At least 18 years of age prior to the scheduled start date
* Completed at least one year of undergraduate studies
Additional qualifications:
* Familiarity with MSD-ECL or Elisa techniques. Basic knowledge on Excel, Prism and other relevant software systems.
Education
Juniors/Seniors majoring in biology, biochemistry, neuroscience or relevant fields
Additional Information
All your information will be kept confidential according to EEO guidelines.
Biogen
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
-
IndustryBiotechnology
-
No. of Employees7,800
-
Website
-
Jobs Posted445
